Newsroom
Off the wire.
An independent desk on the people, policy, and money moving cannabis, plus the science that cuts through the noise.
PolicyThe rescheduling fight isn’t over — the hearing that decides adult-use starts Monday
Medical and FDA-approved products already moved to Schedule III. The June 29 DEA hearing decides whether the rest of the market follows.
3mo ago · 6 min read
BusinessHow live rosin went from connoisseur flex to the fastest-growing category
Solventless was a niche. The sales data says it is now a mainstream concentrate — and the price is finally coming down.
3mo ago · 3 min read
CultureStrikes and smoke lounges: what cannabis culture looks like in a down market
Ascend workers walked out and New Jersey cleared a consumption lounge — two snapshots of an industry growing up under pressure.
3mo ago · 4 min read
BusinessThe other side of the rally: receiverships, restructurings, and a fire-sale market
While the biggest names ring the NYSE bell, the middle of the market is getting restructured out from under itself.
3mo ago · 5 min read
DropsOn the shelf this month: a wrestler’s multi-state rollout and a race to the bottom on price
From RVD420’s seven-state debut to Canopy chasing high potency on a budget, June’s launches show two very different bets.
3mo ago · 3 min read
CultureThe budtender economy: meet the creators turning the counter into content
A new class of dispensary staff is building real audiences — and brands are paying attention.
3mo ago · 3 min read
ScienceNearly 200 studies in: what cannabis research actually showed in the first half of 2026
Past the press releases, the year’s peer-reviewed work points at real medical signal — and a real potency warning.
3mo ago · 7 min read
ScienceThe terpene myths that won’t die — and what the lab data really shows
Indica, sativa, and the comforting story we tell ourselves at the counter.
4mo ago · 3 min read
Page 12 of 12